Table 4 Multiple regression analysis for the risk of developing cancer-associated venous thrombosis
Characteristics | Beta (SE) | OR (95% CI) | P value |
|---|---|---|---|
(Constant) | -5.19 (0.18) | 0.006 (0.004–0.008) | < 0.001 |
Age ≥ 65 vs. < 65 years | 0.47 (0.14) | 1.60 (1.21–2.12) | 0.001 |
BMI ≥ 25 vs. < 25 kg/m2 | 0.43 (0.15) | 1.53 (1.13–2.06) | 0.005 |
Platelet count ≥ 350 vs. < 350 × 103/µL | 0.24 (0.16) | 1.28 (0.92–1.75) | 0.137 |
Hemoglobin < 10 vs. ≥ 10 g/dL | 0.40 (0.20) | 1.49 (0.99–2.15) | 0.043 |
Leukocyte count ≥ 11 vs. < 11 × 103/µL | 0.72 (0.19) | 2.06 (1.41–2.93) | < 0.001 |
CAT risk according to chemotherapeutics High risk vs. not high risk | 0.46 (0.17) | 1.59 (1.15–2.22) | 0.006 |
CAT risk according to cancer site | |||
- High vs. low risk | 0.46 (0.17) | 1.58 (1.14–2.20) | 0.006 |
- Very high vs. low risk | 0.97 (0.20) | 2.64 (1.79–3.87) | < 0.001 |
Diabetes mellitus yes vs. no | -0.08 (0.17) | 0.92 (0.65–1.28) | 0.629 |
Hypertension yes vs. no | 0.18 (0.16) | 1.19 (0.82–1.62) | 0.264 |
Chronic kidney disease yes vs. no | 0.26 (0.24) | 1.30 (0.80–2.02) | 0.270 |
Preexisting antiplatelet yes vs. no | 0.18 (0.20) | 1.20 (0.80–1.75) | 0.369 |